NUVECTIS PHARMA INC.

Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900

21 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial

12 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900

06 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

01 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma

17 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports Second Quarter 2023 Financial Results and Business Highlights

09 Aug 2023 08:00:58 By Nasdaq GlobeNewswire

Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes

20 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces FDA Clearance of NXP900 IND

15 May 2023 08:00:01 By Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports First Quarter 2023 Financial Results and Business Highlights

10 May 2023 08:00:02 By Nasdaq GlobeNewswire

Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

27 Apr 2023 10:14:23 By Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference

27 Apr 2023 08:00:02 By Nasdaq GlobeNewswire

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting

18 Apr 2023 08:00:01 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma

10 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting

17 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference

10 Mar 2023 08:00:00 By Nasdaq GlobeNewswire

Nuvectis Pharma, Inc. Reports Fiscal Year 2022 Financial Results and Business Highlights

07 Mar 2023 08:00:31 By Nasdaq GlobeNewswire

Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress

23 Feb 2023 08:00:02 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces a Publication in The Journal of Experimental Medicine for NXP900 in an In-Vivo Model of Metastatic Castration Resistant Prostate Cancer (“mCRPC”) with Acquired Resistance to Enzalutamide, the Active Ingredient in Xtandi®

09 Feb 2023 08:00:01 By Nasdaq GlobeNewswire

Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

04 Jan 2023 08:00:01 By Nasdaq GlobeNewswire

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

01 Dec 2022 08:00:01 By Nasdaq GlobeNewswire